326 Results for "

CT

" in MedChemExpress (MCE) Product Catalog:
Products (326)

326 Results for "CT" in MCE Product Catalog:

315
315 Publications Verification
Cat. No.: HY-10182
CAS No.: 252917-06-9
Purity:  99.43%
Synonyms: CHIR-99021; CT99021
Research Areas:  

Metabolic Disease Cancer

Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .
loading...
    loading...
315
315 Publications Verification
Cat. No.: HY-10182B
CAS No.: 1782235-14-6
Purity:  99.07%
Synonyms: CHIR-99021 trihydrochloride; CT99021 trihydrochloride
Research Areas:  

Cancer

Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy .
loading...
    loading...
315
315 Publications Verification
Cat. No.: HY-10182A
CAS No.: 1797989-42-4
Purity:  99.93%
Synonyms: CHIR-99021 monohydrochloride; CT99021 monohydrochloride
Research Areas:  

Cancer

Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-128643
CAS No.: 2374782-02-0
Purity:  98.29%
Target:  

FAP

Research Areas:  

Cancer

FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. 68Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-12354
CAS No.: 292605-14-2
Purity:  99.67%
Target:  

MMP

Research Areas:  

Cancer

SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-P9970
CAS No.: 170277-31-3
Synonyms: Avakine; CT-P13; SB2; TA-650
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
The component ratio of this product is Active ingredient : Excipients = 9 : 47.
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-P9970A
Synonyms: Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-10985
CAS No.: 437742-34-2
Purity:  99.13%
Synonyms: Salinosporamide A; NPI-0052
Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, pan-proteasome inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC50=3.5, 28, and 430 nM, respectively) .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712A
CAS No.: 1805789-54-1
Purity:  99.90%
Synonyms: CT7001 hydrochloride; ICEC0942 hydrochloride
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712
CAS No.: 1805833-75-3
Synonyms: CT7001; ICEC0942
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712C
Purity:  98.60%
Synonyms: CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712B
Purity:  99.06%
Synonyms: CT7001 hydrochloride dihydrate; ICEC0942 hydrochloride dihydrate
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P1136
CAS No.: 1507930-57-5
Target:  

Gap Junction Protein

Research Areas:  

Cardiovascular Disease

Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10202
CAS No.: 387867-13-2
Purity:  99.48%
Synonyms: MLN518; CT53518
Target:  

FLT3 c-Kit PDGFR Apoptosis

Research Areas:  

Cancer

Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P1136A
Target:  

Gap Junction Protein

Research Areas:  

Cardiovascular Disease

Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10202A
CAS No.: 2438900-70-8
Purity:  99.78%
Synonyms: MLN518 hydrochloride; CT53518 hydrochloride
Target:  

FLT3 c-Kit PDGFR Apoptosis

Research Areas:  

Cancer

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-70073
CAS No.: 455264-31-0
Synonyms: CT7758
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P77587
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: Calcitonin; CCP; PDN-21; CALCA; CALC1; CGRP; CGRP-I; CGRP1; CT; KC; PCT; Procalcitonin; Calcitonin 1; Katacalcin
Species:  
Source:  
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0984
CAS No.: 13636-18-5
Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0984A
CAS No.: 13042-18-7
Fendiline, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
loading...
    loading...